180 Wealth Advisors LLC Sells 1,269 Shares of Edwards Lifesciences Co. (NYSE:EW)

180 Wealth Advisors LLC trimmed its holdings in Edwards Lifesciences Co. (NYSE:EW) by 11.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,276 shares of the medical research company’s stock after selling 1,269 shares during the period. 180 Wealth Advisors LLC’s holdings in Edwards Lifesciences were worth $940,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in EW. Moneta Group Investment Advisors LLC lifted its holdings in Edwards Lifesciences by 104,971.3% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 15,399,249 shares of the medical research company’s stock valued at $1,148,938,000 after purchasing an additional 15,384,593 shares during the last quarter. Norges Bank acquired a new position in Edwards Lifesciences in the 4th quarter valued at about $658,390,000. Alliancebernstein L.P. raised its holdings in Edwards Lifesciences by 27.5% in the 4th quarter. Alliancebernstein L.P. now owns 21,874,280 shares of the medical research company’s stock valued at $1,632,040,000 after acquiring an additional 4,712,819 shares during the period. Two Sigma Advisers LP lifted its position in Edwards Lifesciences by 161.5% during the fourth quarter. Two Sigma Advisers LP now owns 3,503,803 shares of the medical research company’s stock worth $261,419,000 after acquiring an additional 2,164,100 shares during the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its holdings in shares of Edwards Lifesciences by 655.9% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,325,457 shares of the medical research company’s stock worth $173,502,000 after acquiring an additional 2,017,801 shares during the period. 79.25% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Catherine M. Szyman sold 5,000 shares of the stock in a transaction that occurred on Monday, July 10th. The shares were sold at an average price of $90.52, for a total transaction of $452,600.00. Following the completion of the sale, the vice president now owns 34,814 shares of the company’s stock, valued at approximately $3,151,363.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Edwards Lifesciences news, insider Larry L. Wood sold 8,660 shares of the company’s stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $73.63, for a total transaction of $637,635.80. Following the sale, the insider now owns 213,794 shares of the company’s stock, valued at $15,741,652.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Catherine M. Szyman sold 5,000 shares of Edwards Lifesciences stock in a transaction dated Monday, July 10th. The stock was sold at an average price of $90.52, for a total value of $452,600.00. Following the completion of the transaction, the vice president now directly owns 34,814 shares of the company’s stock, valued at $3,151,363.28. The disclosure for this sale can be found here. Insiders have sold a total of 174,359 shares of company stock valued at $14,301,522 over the last ninety days. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Stock Down 0.4 %

NYSE:EW opened at $72.94 on Tuesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.15 and a quick ratio of 2.30. Edwards Lifesciences Co. has a one year low of $67.13 and a one year high of $94.87. The firm’s 50 day simple moving average is $81.38 and its 200 day simple moving average is $83.98. The company has a market cap of $44.34 billion, a PE ratio of 32.27, a P/E/G ratio of 3.95 and a beta of 1.03.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Wednesday, July 26th. The medical research company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.01. The business had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.51 billion. Edwards Lifesciences had a return on equity of 25.43% and a net margin of 24.56%. Edwards Lifesciences’s quarterly revenue was up 11.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.63 earnings per share. On average, research analysts anticipate that Edwards Lifesciences Co. will post 2.55 earnings per share for the current year.

Analysts Set New Price Targets

EW has been the topic of a number of recent research reports. TheStreet lowered Edwards Lifesciences from a “b-” rating to a “c+” rating in a research note on Wednesday, August 9th. Jefferies Financial Group boosted their target price on shares of Edwards Lifesciences from $103.00 to $107.00 and gave the company a “buy” rating in a research report on Tuesday, July 25th. Piper Sandler lowered their price target on shares of Edwards Lifesciences from $88.00 to $83.00 and set a “neutral” rating on the stock in a research report on Friday, September 8th. Robert W. Baird initiated coverage on shares of Edwards Lifesciences in a report on Tuesday, July 18th. They issued an “outperform” rating and a $107.00 price objective for the company. Finally, 58.com reaffirmed a “reiterates” rating on shares of Edwards Lifesciences in a report on Tuesday, June 27th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Edwards Lifesciences has a consensus rating of “Hold” and an average price target of $92.42.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.